Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise
CTX001 is being evaluated as a one-time treatment for transfusion dependent beta thalassemia and sickle cell disease
Read More
Tag: Cas-9
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
